9.50Open9.50Pre Close0 Volume38 Open Interest35.00Strike Price0.00Turnover78.89%IV3.03%PremiumAug 16, 2024Expiry Date8.19Intrinsic Value100Multiplier25DDays to Expiry1.31Extrinsic Value100Contract SizeAmericanOptions Type0.8714Delta0.0234Gamma4.83Leverage Ratio-0.0413Theta0.0199Rho4.20Eff Leverage0.0239Vega
Dyne Therapeutics Stock Discussion
$XPeng(XPEV.US)$ stock rose 15.56%. Shares of Chinese stocks gained following an increase in China's June exports.
$QuantumScape(QS.US)$ stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen $VOLKSWAGEN A G(VWAGY.US)$ 's battery company PowerC...
GlobeNewswire· 7 mins ago
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months -
- DYNE-101 Showed Improvement in Myotonia, Muscle Strength, ...
loading...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US)$
$Vaxcyte(PCVX.US)$
$Legend Biotech(LEGN.US)$
$Janux Therapeutics(JANX.US)$
$Aerovate(AVTE.US)$
$Rhythm Pharmaceuticals(RYTM.US)$
$Evolent Health(EVH.US)$
$NewAmsterdam Pharma(NAMS.US)$
$RxSight(RXST.US)$
$TYRA BIOSCIENCES, INC.(TYRA.US)$
$Edgewise Therapeutics(EWTX.US)$
$4D Molecular Therapeutics(FDMT.US)$
$Biogen(BIIB.US)$
$PepGen(PEPG.US)$